ADR REPORTS CONFIDENTIALITY PROPOSED RULE
Executive Summary
ADR REPORTS CONFIDENTIALITY PROPOSED RULE would limit the burdens on firms to disclose in law suits the names of reporters and patients experiencing adverse drug events, the Pharmaceutical Manufacturers Association said in March 23 comments submitted by John Siegfried, MD, on FDA's proposed regulation. Commending the proposal, PMA noted that "once adopted, the rule will limit the amount of time companies will have to spend defending against plaintiffs' requests for release of names of patients and reporters."
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth